25194-01-8Relevant articles and documents
Pyridine-containing m-phenylene ethynylene oligomers having tunable basicities
Heemstra, Jennifer M.,Moore, Jeffrey S.
, p. 659 - 662 (2004)
Incorporation of a pyridine monomer into the backbone of a m-phenylene ethynylene oligomer allows functionalization of the interior binding cavity of the folded oligomer. The basicity of the inwardly directed pyridine moiety was modulated by changing the
FUSED PYRIDINE DERIVATIVES
-
, (2012/12/13)
Fused pyridine derivatives shown as the general formula (I), and their pharmaceutically acceptable salts, stereoisomers or solvates thereof are disclosed, which belong to the technical field of medicines. The R1, R2, R3, Q, X and Y substituents in formula (I) are defined as in the description. Also disclosed are the preparation methods, pharmaceutical compositions comprising the compounds and uses of the compounds in the manufacture of the medicine for the treatment and/or prevention of noninsulin-dependent diabetes, hyperglycemia, hyperlipidemia and insulin resistance.
5-Substituted 1H-pyrrolo[3,2-b]pyridines as inhibitors of gastric acid secretion
Palmer, Andreas Marc,Muench, Gabriela,Brehm, Christof,Zimmermann, Peter Jan,Buhr, Wilm,Feth, Martin Philipp,Simon, Wolfgang Alexander
, p. 1511 - 1530 (2008/09/18)
A series of novel 1H-pyrrolo[3,2-b]pyridines was prepared relying on a copper iodide catalyzed cyclization of 2-prop-1-ynylpyridin-3-amines. A structure-activity relationship was established focusing on the influence of the substitution pattern in position 1, 3, and 5 of the heterocycle on anti-secretory activity, lipophilicity, and pKa value. Some of the compounds proved to be potent inhibitors of the gastric acid pump.